GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection

Zorginstituut Nederland has completed its assessment whether the products Rekambys® (rilpivirine, prolonged-release suspension for injection) and Vocabria® (cabotegravir; 30mg film-coated tablet and prolonged-release suspension for injection) can be included in the Medicine Reimbursement System (GVS). The Zorginstituut recommends to include Vocabria® (cabotegravir) and Rekambys® (rilpivirine) in the GVS on List 1B of the Health Insurance Regulation.

Registered indication

The combination treatment with cabotegravir and rilpivirine is the first long-acting intramuscular antiretroviral (HIV-1) treatment. It is indicated for the treatment of HIV-1 infection in adults whose infection is under control with other HIV medicines (HIV-1-RNA < 50 copies/ml). Cabotegravir and rilpivirine are both administered via an intramuscular injection once a month or once every two months. 

Zorginstituut's advice

Vocabria® (cabotegravir) and Rekambys® (rilpivirine) can be included in the GVS on List 1B of the Health Insurance Regulation. 

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.